<div id="readability-page-1"><p>Amicus received a Hold rating and   price target from Needham analyst Gil Blum today.</p><h3>Claim 50% Off TipRanks Premium and Invest with Confidence </h3><ul><li>Unlock  hedge-fund level data  and  powerful investing tools  designed to help you make smarter, sharper decisions  </li><li> Stay ahead of the market with  the latest news and analysis  so your portfolio is always positioned for maximum potential</li></ul> <p>According to TipRanks, Blum is a 4-star analyst with an average return of <span>7.8%</span> and a 39.68% success rate. Blum covers the Healthcare sector, focusing on stocks such as Autolus Therapeutics, Nurix Therapeutics, and Rocket Pharmaceuticals.</p> <p>In addition to Needham, Amicus also received a Hold from Cantor Fitzgerald’s Kristen Kluska in a report issued today. However, on December 17, Citi initiated coverage with a Buy rating on Amicus (NASDAQ: FOLD).</p></div>

FOLD

<p>Amicus (FOLD) was downgraded to a Hold rating by Needham analyst Gil Blum, who also set a price target. Blum is a 4-star analyst with a 7.8% average return. Cantor Fitzgerald's Kristen Kluska also issued a Hold rating, while Citi initiated coverage with a Buy rating on December 17.</p>

Amicus (FOLD) was downgraded to a Hold Rating at Needham